Author Archives: Louise Deis
Distinctive Voices: lectures in Science & Technology at Irvine’s Beckman Center
TRY, Initiative on Plant Traits — database
Welcome to the TRY Initiative on Plant Traits
Quantifying and scaling global plant trait diversity
A network of vegetation scientists jointly headed by
DIVERSITAS, IGBP and the Max Planck Institute for Biogeochemistry
Main objectives:
- Construction of a global database of plant functional traits
- Make the data available for the ecological community
- Support the design of a new generation of global vegetation models
There is a link to a detailed article which has just been published in Global Change Biology.
AIP releases new app for authors and reviewers — iPeerReview
“AIP releases new app for authors and reviewers – 04 Aug 2011
AIP Publishing, a division of the American Institute of Physics (AIP), has announced the release of its new app, iPeerReview. The new app allows authors and reviewers to use their iPhone, iPad, and iPod touch devices to access a broad range of information on papers submitted to any of AIP’s journals in Peer X-Press, AIP’s manuscript submission and review system.
Once logged in, users can perform a number of activities related to their papers. They can access a list of all active and completed papers, view the status history of a paper, view and save a paper in PDF format, email a paper, and link to a paper on AIP’s Scitation platform if it is in production or to Peer X-Press if it is under review.
When users access iPeerReview, they can either log in or access papers that they have previously saved to their device. The app will determine if they are an author, a reviewer, or both. In the event that they are both an author and a reviewer, iPeerReview will allow them to access both sets of papers under separate tabs.”
Source: Knowledgespeak Newsletter
JISC announces support for govt. recommendations for peer review process changes
JISC (Joint Information Systems Committee) in the U.K. is supporting an open peer review process. It should be more transparent and reviewers should be trained. JISC also recommends the sharing of data in the scientific community, and there is mention in this brief of the Dryad project to facilitate this sharing of data in a repository.
“The recommendations came out of a House of Commons Science and Technology
Committee report that also urged that researchers make their scientific data
publicly available, and that reviewers have formal training.”
Source: Knowledgespeak Newsletter, Aug. 2, 2011.
Open Access Coalition
Today Kansas and 21 other
universities and colleges announced that they’re joining forces to form the
Coalition of Open Access Policy Institutions, or Coapi. The new group will
“collaborate and share implementation strategies, and advocate on a national
level,” it said in a statement.
Read more: http://bit.ly/p8A9eo
Source: Trevor Dawes, Circulation Services Director, Princeton Univ.
Open Access — 1st North American Meeting
SPARC to host first North American meeting on Open Access in 2012 |
The Scholarly Publishing and Academic Resources Coalition (SPARC) will host its first North American meeting on Open Access in 2012. The first of its kind, the event will expand on the successful biennial SPARC Digital Repositories meeting. Source: Knowledgespeak Newsletter July 27, 2011 |
Cambridge Journals — Open Access through August 30, 2011
” Cambridge Journals open access to online content published during 2009 and 2010 – 18 Jul 2011
Cambridge Journals, a division of Cambridge University Press (CUP), UK, is celebrating recent achievements by making all its online journals content from 2009 and 2010 free for six weeks.
Cambridge has enjoyed accelerating success in recent years with increasing numbers of journals published, improved impact factors and multiple enhancements made to Cambridge Journals Online (CJO). Usage has significantly increased with the digitisation of new and archive content, and more people are now able to access Cambridge Journals than before. Currently over 1.3 million articles are downloaded from CJO every month.
To celebrate these successes, and to reach out to new customers, Cambridge Journals has announced that it is making all online content published during 2009 and 2010 free between July 15 and August 30, 2011.
During the trial, the Cambridge Journals team will also be looking for feedback to help shape the future of the service. The CJO website is continually developing, informed by consultation with key customers in the academic and library communities. Users will be encouraged to give their feedback on CJO and content, to ensure the service keeps on developing according to their needs.”
Knowledgespeak Newsletter, July 18, 2011
The Science & Entertainment Exchange — NAS
“The Science & Entertainment Exchange is a program of the National Academy of Sciences that connects entertainment industry professionals with top scientists and engineers to create a synergy between accurate science and engaging storylines in both film and TV programming.” Learn More
Virtual Drug Discovery — Nimbus
Editor’s Corner of Fierce BioTech IT .com 5/16/11
“My visit to Nimbus, Bill Gates’ bet on virtual drug discovery
By Ryan McBride |
Microsoft ($MSFT) chairman Bill Gates was announced as one of Nimbus’ seed investors in March, raising the profile of the young firm and shedding light on its unique relationship with Schrödinger, in which Gates invested last year through his Cascade Investment group. Nimbus hasn’t disclosed how much it has brought from Gates, Atlas and its other seed investors, yet more details could be in the offing; the company is planning a Series A round of funding in the near future.
Schrödinger, a global provider of chemistry simulation software for pharmaceutical companies, is a major shareholder in Nimbus. Ramy Farid, Schrödinger’s president, co-founded Nimbus with Atlas’ Booth in 2009 and sits on its board, the chairman says. The start-up has special access to Schrödinger’s software, support from the 21-year-old company’s computational chemistry experts and business expertise from Atlas.
While it’s too early to say with Nimbus’ drugs will succeed in clinical trials, the upstart has been able to show how the use of new software for understanding disease proteins and other tools have helped speed its drug discovery efforts, according to Booth. Read the full article >>“